About
Who We Are
Management Team
Scientific Advisors
Board of Directors
Pipeline & Research
Pipeline
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaborations
Expanded Access Policy
NEWS & MEDIA
Investors
Stock Overview
Events & Presentations
Financials & Filings
ESG
Corporate Governance
Careers
Contact Us
Select Page
Corporate Presentation
September 15, 2023
09.2023
Corporate Presentation
Download
Search for:
RECENT NEWS ARTICLES
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
BeyondSpring Files 2022 Annual Report on Form 20-F
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
RECENT MEDIA COVERAGE
TD Ameritrade Watch List
Managing Chemotherapy Toxicities for Improved Patient Outcomes
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring
We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.
Ok
Privacy policy
